title: High PMTCT program uptake and coverage of mothers, their partners, and babies in northern Uganda: achievements and lessons learned over 10 years of implementation (2002-2011).
abstract: BACKGROUND
  The international nongovernmental organization "AVSI Foundation" has been actively supporting Uganda's Ministry of Health (MoH) prevention of mother-to-child HIV transmission (PMTCT) program since 2002 in 4 districts of the conflict-ridden Acholi subregion in Northern Uganda.
  
  
  OBJECTIVE
  This article presents data covering 10 years of MoH/AVSI PMTCT program activities in Northern Uganda.
  
  
  METHODS
  The program followed Uganda MoH PMTCT guidelines and aimed to be comprehensive, emphasizing social and medical care and support. Data were collected from 24 health facilities from January 2002 to December 2011. Trend analyses were carried out using Predictive Analytics SoftWare (PASW) Statistics 18.
  
  
  RESULTS
  Of the 140,658 women who newly attended antenatal care services from 2002 to 2011, 94.4% received HIV testing and counseling and 6.2% tested HIV-positive. HIV testing and counseling of male partners of tested pregnant women steadily increased from 5.9% in 2002 to 75.8% in 2011, compared with 15.5% in 2011 nationally. Overall, 79.0% of HIV-positive women were started on antiretroviral prophylaxis (69.4%) or triple antiretroviral therapy (9.6%), compared with 52% nationally in 2011. The proportion of HIV-positive women who delivered in health facilities significantly increased from 55.8% in 2004 to 81.1% in 2011 (no national data available). HIV prevalence among HIV-exposed infants tested at or below 18 months of age significantly decreased from 10.3% in 2004 to 5.0% in 2011.
  
  
  CONCLUSIONS
  Our results show how a comprehensive PMTCT program emphasizing social and community engagement alongside medical care and support can succeed in a remote setting with multiple challenges.
authors.affiliation: AVSI Uganda, Kampala, Uganda. femke.bannink@avsi.org
authors.forename: Femke
authors.initials: F
authors.lastname: Bannink-Mbazzi
authors.forename: Massimo
authors.initials: M
authors.lastname: Lowicki-Zucca
authors.forename: Lawrence
authors.initials: L
authors.lastname: Ojom
authors.forename: Sarah V
authors.initials: SV
authors.lastname: Kabasomi
authors.forename: Godfrey
authors.initials: G
authors.lastname: Esiru
authors.forename: Jaco
authors.initials: J
authors.lastname: Homsy
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use*; D000914:Antibodies, Viral / Q000097:blood; D004279:DNA, Viral / Q000737:chemistry / Q000235:genetics; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000453:epidemiology / Q000517:prevention & control* / Q000635:transmission* / Q000821:virology; D006801:Humans; D007223:Infant; D018445:Infectious Disease Transmission, Vertical / Q000517:prevention & control*; D008297:Male; D009035:Mothers; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000821:virology*; D015995:Prevalence; D012747:Sexual Partners; D014454:Uganda
chemical_list: D019380:Anti-HIV Agents; D000914:Antibodies, Viral; D004279:DNA, Viral